AGAnja Garritsen

Anja Garritsen

*This is an algorithmically generated author record based on publicly available information.

Anja Garritsen has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Comparison of Tests for Detecting Prior Exposure to Coxiella burnetii for Use with Q-VAX in Australian Human Q Fever Vaccination

    by Stephen Graves, Jennifer Robson, Anja Scholzen, Richard Dzeng, Francisca Powell-Romero, Jennifer Evans, John Stenos, Meg Jeppesen, Milou L. C. E. Kouwijzer, Jordi Lankhof, et al.

    Background/Objectives: Q-VAX vaccine, approved in Australia, prevents Q fever. However, individuals with prior Coxiella burnetii (Cb) infection have an increased risk of adverse reactions, requiring pre-vaccination screening by an intradermal hypersensitivity skin test for cell-mediated immune memory and a serological assay for anti-Cb antibodies. The week-long interval for skin test assessment limits efficient vaccination. This study evaluated a standardized interferon-γ release assay (IGRA) as a potential skin test alternative. Methods: Immune assays were compared in Australian populations with different incidences of prior Cb exposure. Cell-mediated immunity was assessed by the Q-VAX skin test and IGRA. Serological status was evaluated with established diagnostic assays. Hypothetical vaccine eligibility decisions using combined IGRA and serology results were compared with actual clinical decisions made using current guidelines. Results: All tests performed better in detecting prior infection than in detecting prior vaccination. Only the IGRA identified all individuals with a known history of Q fever. Agreement between the skin test and IGRA was limited. Moderate agreement was observed between hypothetical vaccine eligibility determinations based on IGRA plus serology results and actual clinical decisions. IGRA-positive but serology- and skin test-negative individuals received Q-VAX without clinically significant side effects, suggesting that elevated IGRA responses alone are not predictive of susceptibility to vaccine reactogenicity. Conclusions: The IGRA is not yet a suitable skin test replacement when assessing eligibility for Q fever vaccination, despite the significant limitations of the latter. We offer recommendations for designing future studies that might allow the development of appropriate guidelines for IGRA use in vaccine eligibility screening.

  • Open Access

    Discrepancies in widely used serological methods to detect Borrelia infections may cause missed Lyme diagnoses

    by Elena Volokhina, Annette Stemerding, Yesper Smits, Jordi Lankhof, Milou Kouwijzer, Anja Garritsen

    Accurate diagnosis of Lyme disease, caused by Borrelia burgdorferi , is essential for timely treatment and prevention of long-term complications. This study investigates discrepancies in widely used serological assays and their impact on diagnostic sensitivity in high-risk populations. We analyzed samples from an annual Lyme screening program conducted by Innatoss Laboratories between November 2020 and May 2022, targeting individuals with occupational exposure to ticks. A retrospective cohort of 60 positive serum samples from 57 participants (aged 23–64) was evaluated using three tier one protocols: EUROIMMUN/ZEUS ELISA, SERION ELISA, and Diasorin CLIA, followed by Viramed immunoblots for confirmation. Our findings revealed significant variability in test sensitivity: the EUROIMMUN/ZEUS protocol detected 96.8% of cases, compared to 84.1% for SERION (p = 0.023) and 69.8.0% for Diasorin (pBorrelia infections were missed due to test selection, as confirmed by longitudinal comparison with previous samples. One case study illustrated the clinical consequences of missed diagnoses, including delayed treatment and symptom persistence. These results underscore the need for standardized serological protocols and routine longitudinal sample comparison. We propose the establishment of a consensus panel to define assay performance criteria and recommend integration of electronic health records with laboratory systems to enable automated historical data retrieval. Adoption of more sensitive testing strategies and harmonized interpretation guidelines could significantly improve diagnostic accuracy and patient outcomes in Lyme disease. Summary box: What is already known about this subject: Lyme disease diagnosis relies heavily on serological testing. The two-tier testing protocol is widely used but varies in sensitivity depending on the assays employed. Serological tests cannot distinguish between past and recent infections without longitudinal data. High-risk populations, such as outdoor workers, benefit from regular Lyme screening to detect missed infections. What are the new findings: Significant discrepancies that exist between commonly used serological assays affect diagnostic outcomes. Six recent Borrelia infections were missed due to the choice of test. Comparing current results with previous samples from the same individual improves diagnostic accuracy. What is the possible impact of this study on clinical practice in the foreseeable future?: Increased awareness of test limitations may lead to earlier and more accurate treatment, reducing long-term complications. Standardization and harmonization of Lyme serology can improve future diagnostic guidelines and laboratory practices. Routine comparison of longitudinal samples should become standard practice in Lyme screening programs.

  • Open Access

    Asymmetric Mach–Zehnder Interferometric Biosensing for Quantitative and Sensitive Multiplex Detection of Anti-SARS-CoV-2 Antibodies in Human Plasma

    by Geert Besselink, Anke Schütz-Trilling, Janneke Veerbeek, Michelle Verbruggen, Adriaan van der Meer, Rens Schonenberg, Henk Dam, Kevin Evers, Ernst Lindhout, Anja Garritsen, et al.

    The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has once more emphasized the urgent need for accurate and fast point-of-care (POC) diagnostics for outbreak control and prevention. The main challenge in the development of POC in vitro diagnostics (IVD) is to combine a short time to result with a high sensitivity, and to keep the testing cost-effective. In this respect, sensors based on photonic integrated circuits (PICs) may offer advantages as they have features such as a high analytical sensitivity, capability for multiplexing, ease of miniaturization, and the potential for high-volume manufacturing. One special type of PIC sensor is the asymmetric Mach–Zehnder Interferometer (aMZI), which is characterized by a high and tunable analytical sensitivity. The current work describes the application of an aMZI-based biosensor platform for sensitive and multiplex detection of anti-SARS-CoV-2 antibodies in human plasma samples using the spike protein (SP), the receptor-binding domain (RBD), and the nucleocapsid protein (NP) as target antigens. The results are in good agreement with several CE-IVD marked reference methods and demonstrate the potential of the aMZI biosensor technology for further development into a photonic IVD platform.


  • Open Access

    Natural Exposure- and Vaccination-Induced Profiles of Ex Vivo Whole Blood Cytokine Responses to Coxiella burnetii

    by Susan Raju Paul, Anja Scholzen, Ghazel Mukhtar, Stephanie Wilkinson, Peter Hobson, Richard K. Dzeng, Jennifer Evans, Jennifer Robson, Rowland Cobbold, Stephen Graves, et al.

    Q fever is a zoonotic disease caused by the highly infectious Gram-negative coccobacillus, Coxiella burnetii (C. burnetii). The Q fever vaccine Q-VAX® is characterised by high reactogenicity, requiring individuals to be pre-screened for prior exposure before vaccination. To date it remains unclear whether vaccine side effects in pre-exposed individuals are associated with pre-existing adaptive immune responses to C. burnetii or are also a function of innate responses to Q-VAX®. In the current study, we measured innate and adaptive cytokine responses to C. burnetii and compared these among individuals with different pre-exposure status. Three groups were included: n=98 Dutch blood bank donors with unknown exposure status, n=95 Dutch village inhabitants with known natural exposure status to C. burnetii during the Dutch Q fever outbreak of 2007-2010, and n=96 Australian students receiving Q-VAX® vaccination in 2021. Whole blood cytokine responses following ex vivo stimulation with heat-killed C. burnetii were assessed for IFNγ, IL-2, IL-6, IL-10, TNFα, IL-1β, IP-10, MIP-1α and IL-8. Serological data were collected for all three cohorts, as well as data on skin test and self-reported vaccine side effects and clinical symptoms during past infection. IFNγ, IP-10 and IL-2 responses were strongly elevated in individuals with prior C. burnetii antigen exposure, whether through infection or vaccination, while IL-1β, IL-6 and TNFα responses were slightly increased in naturally exposed individuals only. High dimensional analysis of the cytokine data identified four clusters of individuals with distinct cytokine response signatures. The cluster with the highest levels of adaptive cytokines and antibodies comprised solely individuals with prior exposure to C. burnetii, while another cluster was characterized by high innate cytokine production and an absence of C. burnetii-induced IP-10 production paired with high baseline IP-10 levels. Prior exposure status was partially associated with these signatures, but could not be clearly assigned to a single cytokine response signature. Overall, Q-VAX® vaccination and natural C. burnetii infection were associated with comparable cytokine response signatures, largely driven by adaptive cytokine responses. Neither individual innate and adaptive cytokine responses nor response signatures were associated retrospectively with clinical symptoms during infection or prospectively with side effects post-vaccination.


  • Open Access

    Whole Blood Interferon γ Release Is a More Sensitive Marker of Prior Exposure to Coxiella burnetii Than Are Antibody Responses

    by Anja Scholzen, Margot de Vries, Hans-Peter Duerr, Hendrik-Jan Roest, Ann E. Sluder, Mark C. Poznansky, Milou L. C. E. Kouwijzer, Anja Garritsen

    For the zoonotic disease Q fever, serological analysis plays a dominant role in the diagnosis ofCoxiella burnetiiinfection and in pre-screening for past exposure prior to vaccination. A number of studies suggest that assessment ofC. burnetii-specific T-cell IFNγ responses may be a more sensitive tool to assess past exposure. In this study, we assessed the performance of a whole bloodC. burnetiiIFNγ release assay in comparison to serological detection in an area of high Q fever incidence in 2014, up to seven years after initial exposure during the Dutch Q fever outbreak 2007-2010. In a cohort of >1500 individuals from the Dutch outbreak village of Herpen, approximately 60% had mounted IFNγ responses toC. burnetii. This proportion was independent of theCoxiellastrain used for stimulation and much higher than the proportion of individuals scored sero-positive using the serological gold standard immunofluorescence assay. Moreover,C. burnetii-specific IFNγ responses were found to be more durable than antibody responses in two sub-groups of individuals known to have sero-converted as of 2007 or previously reported to the municipality as notified Q fever cases. A novel ready-to-use version of the IFNγ release assay assessed in a subgroup of pre-exposed individuals in 2021 (10-14 years post exposure) proved again to be more sensitive than serology in detecting past exposure. These data demonstrate thatC. burnetii-induced IFNγ release is indeed a more sensitive and durable marker of exposure toC. burnetiithan are serological responses. In combination with a simplified assay version suitable for implementation in routine diagnostic settings, this makes the assessment of IFNγ responses a valuable tool for exposure screening to obtain epidemiological data, and to identify previously exposed individuals in pre-vaccination screens.


  • Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies

    by Anja Garritsen, Anja Scholzen, Daan W. A. van Den Nieuwenhof, Anke P. F. Smits, E. Suzan Datema, Luc S. van Galen, Milou L. C. E Kouwijzer

    Serological testing in the COVID-19 pandemic is mainly implemented to gain sero-epidemiological data, but can also retrospectively inform about suspected SARS-CoV-2 infection.We verified and applie...


  • Open Access

    Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies

    by Anja Garritsen, Anja Scholzen, Daan W.A. van Den Nieuwenhof, Anke P.F. Smits, Esther Suzan Datema, Luc S. van Galen, Milou L.C.E. Kouwijzer

    Serological testing in the COVID-19 pandemic is mainly implemented to gain sero-epidemiological data, but can also retrospectively inform about suspected SARS-CoV-2 infection. We verified and applied a two-tiered testing strategy combining a SARS-CoV-2 receptor-binding domain (RBD)-specific lateral flow assay (LFA) with a nucleocapsid protein (NCP) IgG ELISA to assess seroconversion in n=7241 individuals. The majority had experienced symptoms consistent with COVID-19, but had no access to RT-PCR testing. Longitudinal follow-up in n=97 LFA+ individuals was performed up to 20 weeks after initial infection using NCP and spike protein S1 domain (S1) IgG ELISAs and a surrogate virus neutralization test (sVNT). Individuals reporting symptoms from January 2020 onwards showed seroconversion, as did a considerable proportion of asymptomatic individuals. Seroconversion for symptomatic and asymptomatic individuals was higher in an area with a known infection cluster compared to a low incidence area. Overall, 94% of individuals with a positive IgG result by LFA were confirmed by NCP ELISA. The proportion of ELISA-confirmed LFA results declined over time, in line with contracting NCP IgG titers during longitudinal follow-up. Neutralizing antibody activity was considerably more stable than S1 and NCP IgG titers, and both reach a plateau after approximately 100 days. The sVNT proved to be not only highly specific, but also more sensitive than the specificity-focussed two-tiered serology approach. Our results demonstrate the high specificity of two-tiered serology testing and highlight the sVNT used as a valuable tool to support modelling of SARS-CoV-2 transmission dynamics, complement molecular testing and provide relevant information to individuals.


  • Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever

    by Anja Scholzen, Guilhem Richard, Leonard Moise, Eva Hartman, Chantal P. Bleeker-Rovers, Patrick M. Reeves, Susan Raju Paul, William D. Martin, Anne S. De Groot, Mark C. Poznansky, et al.

    Infection with Coxiella burnetii , the causative agent of Q fever, can result in life-threatening persistent infection. Reactogenicity hinders worldwide implementation of the only licensed human Q fever vaccine. We previously demonstrated long-lived immunoreactivity in individuals with past symptomatic and asymptomatic Coxiella infection (convalescents) to promiscuous HLA class II C. burnetii epitopes, providing the basis for a novel T-cell targeted subunit vaccine.


  • Open Access

    Coxiella burnetii epitope-specific T-cell responses in chronic Q fever patients

    by Anja Scholzen, Guilhem Richard, Leonard Moise, Eva Hartman, Chantal P. Bleeker-Rovers, Patrick M. Reeves, Susan Raju Paul, William D. Martin, Anne S. De Groot, Mark C. Poznansky, et al.

    Infection with Coxiella burnetii , the causative agent of Q fever, can result in life-threatening persistent infection. Reactogenicity hinders worldwide implementation of the only licensed human Q fever vaccine. We previously demonstrated long-lived immunoreactivity in individuals with past symptomatic and asymptomatic Coxiella infection (convalescents) to promiscuous HLA-class II C. burnetii epitopes, providing the basis for a novel T-cell-targeted subunit vaccine. Here we investigated in a cohort of 22 individuals with persistent infection (chronic Q fever) whether they recognize the same set of epitopes, or distinct epitopes that could be candidates for a therapeutic vaccine or aid in the diagnosis of persistent infection. Individuals with chronic Q fever showed strong class II epitope-specific cultured ELISpot responses largely overlapping with the peptide repertoire identified previously for convalescents. Five additional peptides were recognized more frequently by chronic subjects, but there was no combination of epitopes uniquely recognized by or non-reactive in chronic Q fever subjects. Consistent with more recent/prolonged exposure, we found, however, stronger direct ex vivo responses to whole-cell C. burnetii and individual peptides in direct ELISpot than in convalescents. In conclusion, we have validated and expanded a previously published set candidate epitopes for a novel T-cell targeted subunit Q fever vaccine in the context of chronic Q fever patients and demonstrated that they successfully mounted a T-cell response comparable to that of convalescents. Finally, we demonstrate that individuals treated for chronic Q fever mount a broader ex vivo response to class II epitopes than convalescents, which could be explored for diagnostic purposes.